Physician profile
Patrick W Thomas
NPI 1942203583
$3,642.52
in general payments reported to CMS, 2019-2025
28 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,984 · 2020: $648 · 2021: $410 · 2022: $292 · 2023: $162 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $512.33 | 2019-2022 | |
| Amgen INC. | $413.38 | 2019-2025 | Repatha |
| Abbott Laboratories | $338.48 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $313.34 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $275.22 | 2019-2021 | |
| Genzyme Corporation | $274.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $249.81 | 2019-2020 | |
| Pfizer INC. | $210.32 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.44 | 2019-2021 | |
| Amarin Pharma, INC. | $190.51 | 2019-2021 | |
| Novo Nordisk INC | $142.41 | 2021 | |
| Lantheus Medical Imaging, INC. | $70.40 | 2019 | |
| Gilead Sciences, INC. | $56.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $54.13 | 2019-2020 | |
| Biotronik INC. | $40.75 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $39.64 | 2020 | |
| Medicomp INC | $37.48 | 2023 | Telepatch Cardiac Monitor |
| Regeneron Healthcare Solutions, INC. | $25.25 | 2019 | |
| Irhythm Technologies, INC. | $23.78 | 2020 | |
| Medtronic, INC. | $22.73 | 2022 | |
| Esperion Therapeutics, INC. | $22.23 | 2020 | |
| Akcea Therapeutics, INC. | $20.60 | 2019 | |
| Portola Pharmaceuticals, LLC | $20.36 | 2019 | |
| Lundbeck LLC | $19.95 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.69 | 2019 | |
| Medtronic Vascular, INC. | $18.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.21 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.